Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ardelyx, Inc. (ARDX : NSDQ)
 
 • Company Description   
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Number of Employees: 395

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.92 Daily Weekly Monthly
20 Day Moving Average: 4,464,435 shares
Shares Outstanding: 240.98 (millions)
Market Capitalization: $1,426.62 (millions)
Beta: 0.66
52 Week High: $6.78
52 Week Low: $3.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 13.85% 11.99%
12 Week 9.63% 1.97%
Year To Date 16.76% 0.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Fifth Avenue Suite 210
-
Waltham,MA 02451
USA		 ph: 510-745-1700
fax: 510-745-0493		 investor@ardelyx.com http://www.ardelyx.com
 
 • General Corporate Information   
Officers
Michael Raab - President and Chief Executive Officer
David Mott - Chairman
Justin Renz - Chief Financial and Operations Officer
Robert Bazemore - Director
Richard Rodgers - Director

Peer Information
Ardelyx, Inc. (GSAC)
Ardelyx, Inc. (CASI)
Ardelyx, Inc. (ALCD.)
Ardelyx, Inc. (OMNN)
Ardelyx, Inc. (CGPI.)
Ardelyx, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 039697107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/19/26
Share - Related Items
Shares Outstanding: 240.98
Most Recent Split Date: (:1)
Beta: 0.66
Market Capitalization: $1,426.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/19/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.25
Price/Cash Flow: -
Price / Sales: 3.58
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: 12.30%
vs. Previous Quarter: 12.97%
ROE
09/30/25 - -36.91
06/30/25 - -36.57
03/31/25 - -34.45
ROA
09/30/25 - -12.57
06/30/25 - -13.42
03/31/25 - -13.81
Current Ratio
09/30/25 - 4.41
06/30/25 - 4.30
03/31/25 - 4.12
Quick Ratio
09/30/25 - 4.11
06/30/25 - 4.03
03/31/25 - 3.81
Operating Margin
09/30/25 - -14.20
06/30/25 - -14.60
03/31/25 - -14.86
Net Margin
09/30/25 - -14.20
06/30/25 - -14.60
03/31/25 - -14.86
Pre-Tax Margin
09/30/25 - -13.95
06/30/25 - -14.36
03/31/25 - -14.59
Book Value
09/30/25 - 0.64
06/30/25 - 0.58
03/31/25 - 0.61
Inventory Turnover
09/30/25 - 2.03
06/30/25 - 2.99
03/31/25 - 3.18
Debt-to-Equity
09/30/25 - 1.31
06/30/25 - 1.44
03/31/25 - 1.04
Debt-to-Capital
09/30/25 - 56.71
06/30/25 - 59.08
03/31/25 - 50.95
 

Powered by Zacks Investment Research ©